Skip to main content
. 2016 Jun 27;213(7):1331–1352. doi: 10.1084/jem.20151517

Table 2. JEV peptides eliciting T cell responses identified in this study.

Subject Peptide Subset JEV protein Amino acid location Type HLA restriction HLA class I HLA class II
A B C DR
JE082/2 GKNRAINMLKRGLPRVF CD4 C 9–25 JE 11:01, 33:01 13:01, 44:02 DR12, DR14, DR52
VFPLVGVKRVVMSLLDGR CD4 C 24–41
JE093/2 MLKRGLPRVFPLVGVKRVVMSLLDGR CD4 C 16–41 JE 24:02, 24:02 13:01, 27:02 DR15, DR51
JE043/2 SLVNKKEAWLDSTKATRY CD8 M 230–247 JE 01:01, 11:01 52:01, 57:01 DR3, DR15, DR52, DR51
WIIRNPGYAFLAAVLGWM CD4 M 254–271
JE101/2 RYLMKTENWIIRNPGYAF CD4 M 246–263 JE 30:01, 33:01 13:01, 44:02 DR7, DR53
JE017/2 AKFSCTSKAIGRTIQ CD4 E 411–425 JE 03:01, 11:02 07:02, 35:01 DR4, DR11, DR52, DR53
KQSVVALGSQEGGLHQAL CD4 E 543–560
CRLKMDKLALKGTTYGMCTEKFSF CD4 E 581–604
HGTVVIELSYSGSDGPCK CD4 E 613–630
LGKAFSTTLKGAQRLAAL CD4 E 697–714
WDFGSIGGVFNSIGKAVHQVFGGAF CD4 E 719–735
GVLVFLATNVHADTGCAI CD4 E 783–801
H021/1 PWTSPSSTAWRNRELLM CD4 E 518–534 H 02:01, 11:01 07:02, 52:01 DR15, DR51
JE003/2 KYLPETPRSLAKIVHK CD4 + CD8 NS1 827–842 JE 03:01, 33:01 15:01, 37:01 DR10, DR15, DR51
AVHSDLSYWIESRYNDTWKLERAVF CD4 NS1 987–1011
WIESRYNDTWKLERAVFGEVKSCTW CD4 NS1 995–1019
JE001/2 EAWVDRYKYLPETPRSLAKIVHK CD4 NS1 820–842 JE 11:01, 31:01 35:01, 52:21 DR4, DR15, DR53, DR51
TYALNTFTNIAVQLVRLM CD8 NS5 3136–3153
H014/3 TAVLAPTRVVAAEMAEAL CD8 NS3 1723–1740 H 03:01, 30:01 07:02, 13:01 06:02, 07:01
H001/1 ALRGLPVRY CD8 NS3 1739–1747 H 11:01, 32:01 15:01, 55:01 01:02, 04:01
H001/4 DVMCHATL CD8 NS3 1763–1770 D B*08:01 01:01, 03:01 08:01, 44:02 05:01, 07:01 DR8, DR17, DR52
H019/1 NLFVMDEAHFTDPASI CD8 NS3 1784–1799 H 02:01 38:01, 40:06 07:01, 15:02
EAHFTDPASIAARGYI CD8 NS3 1790–1805
H013/3 NLFVMDEAHFTDPASI CD4 NS3 1784–1799 H 02:01, 24:02 35:03, 40:06 02:21, 15:02
EAHFTDPASIAARGYI CD4 + CD8 NS3 1790–1805
GEAAAIFMT CD8 NS3 1812–1820
JE098/2 ELGEAAAIFMTATPP CD8 NS3 1810–1824 JE 02:01 35:01, 40:06 04:01, 07:01
H005/1 GCGRGGWSYYAATLKKV CD8 NS5 2608–2624 H 02:01, 30:01 13:01, 38:01 06:02, 12:02
RGYTKGGAGHEEPMLM CD8 NS5 2628–2643
H010/4 LMQSYGWNL CD8 NS5 2642–2650 D 01:01, 02:01 08:01, 35:01 04:01, 07:01
LVSLKSGVDVFYKPS CD8 NS5 2650–2664
YMPKVIEKMEV CD8 NS5 2714–2724
NMTSQVLLGRMDRTVWR CD8 NS5 2761–2777
HPYRTWTY CD8 NS5 2827–2834 B*35:01
TPFGQQRVF CD4 + CD8 NS5 2873–2884
JE080/2 KLNAMSREEFFKYRREAIIEVDR CD4 NS5 2542–2564 JE 02:01, 33:01 15:05, 44:02 DR7, DR53
TWHKDPEHPYRTWTYHGSYEVK CD4 NS5 2820–2841
H007/2 TMAMTDTTPFGQQRVFK CD4 + CD8 NS5 2869–2885 H 01:01, 68:01 57:01 DR53, DR7
H011/3 TMAMTDTTPFGQQRVFK CD8 NS5 2869–2885 H 02:01, 68:01 37:01, 51:01 06:02, 15:02
H007/3 TMAMTDTTPFGQQRVFK CD4 + CD8 NS5 2869–2885 H 11:01, 68:01 07:02, 52:02 07:01, 12:02
CTKEEFIKKVNSNAAL CD8 NS5 2923–2938
DIAGKQGGKMYADDTAGW CD4 NS5 3050–3067
H002/3 IWFMWLGARY CD8 NS5 3003–3012 H 01:01, 29:01 07:05, 57:01 06:02, 15:04
RYLEFEALGFL CD4 NS5 3011–3021
JE054/2 AISGDDCVVKPLDDRFATALHFL CD8 NS5 3191–3213 JE 11:01, 24:02 15:25, 51:01 07:01, 16:01
JE074/2 CVVKPLDDRFATALHFL CD8 NS5 3197–3213 JE
H008/4 MTTEDMLQVW CD4 + CD8 NS5 3336–3345 H B*58:01 01:01, 33:03 58:01, 15:17 07:01, 03:04 DR13, DR15, DR51, DR52
CSAVPVDW CD8 NS5 3312–3319 B*58:01
JE446/2 GEWMTTEDMLQVWNRVWI CD4 NS5 3333–3350 JE 01:01, 33:01 52:01, 58:01 DR14, DR15, DR52, DR51
MLQVWNRVWIEENEWMM CD8 NS5 3341–3357

JE, recovered JE patient; H, healthy JEV-exposed donor; D, dengue exposed. In total, 57 responses to 40 peptides (or adjacent pairs of peptides) were identified.